uniQure (NASDAQ:QURE) Given Average Rating of “Moderate Buy” by Brokerages

Shares of uniQure (NASDAQ:QURE) have received a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $17.00.

QURE has been the subject of a number of analyst reports. Raymond James reaffirmed an “outperform” rating and issued a $20.00 price target on shares of uniQure in a research report on Thursday, October 10th. The Goldman Sachs Group decreased their price target on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of uniQure in a research report on Wednesday, November 6th. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Thursday, October 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 target price on shares of uniQure in a research note on Wednesday, November 6th.

uniQure Trading Down 5.8 %

Shares of NASDAQ:QURE opened at $5.82 on Wednesday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The stock has a market capitalization of $283.67 million, a price-to-earnings ratio of -1.17 and a beta of 0.90. The company has a 50 day moving average price of $5.91 and a 200 day moving average price of $5.93. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. On average, research analysts anticipate that uniQure will post -3.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of uniQure by 11.4% in the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after buying an additional 109,740 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of uniQure by 133.1% during the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock worth $3,189,000 after acquiring an additional 350,291 shares during the last quarter. Carlson Capital L P lifted its position in shares of uniQure by 16.6% in the 1st quarter. Carlson Capital L P now owns 227,400 shares of the biotechnology company’s stock worth $1,182,000 after purchasing an additional 32,400 shares during the period. Ikarian Capital LLC boosted its position in uniQure by 198.1% during the first quarter. Ikarian Capital LLC now owns 469,133 shares of the biotechnology company’s stock valued at $2,439,000 after acquiring an additional 311,768 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in uniQure during the second quarter worth approximately $79,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.